GKOS
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock trades at a massive premium; Graham Number is not applicable due to lack of earnings.
- Forward P/E of 282.75
- P/S of 14.08
- P/B of 10.70
Growth rates are significantly higher than sector averages.
- 35.7% YoY Revenue Growth
- Strong Q/Q growth trajectory
- High gross margins
- Uncertainty on timeline to net profitability
Historical trend shows a company scaling revenue but failing to capture bottom-line profit.
- Consistent revenue expansion
- Improving EPS surprises in recent quarters
- 25 quarters of negative earnings
Balance sheet is very healthy, mitigating bankruptcy risk despite losses.
- Piotroski F-Score 5/9
- Low Debt/Equity (0.16)
- High Quick Ratio (3.83)
- Negative ROE and ROA
Growth-stage company reinvesting all capital.
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GKOS and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GKOS
Glaukos Corporation
Primary
|
+24.9% | +156.9% | +30.1% | +61.3% | +18.3% | -2.0% |
|
KYMR
Kymera Therapeutics, Inc.
Peer
|
+170.6% | +171.2% | +279.7% | +48.7% | +4.3% | -0.4% |
|
IBRX
ImmunityBio, Inc.
Peer
|
-54.8% | +372.7% | +195.9% | +208.5% | -12.0% | -0.3% |
|
PTGX
Protagonist Therapeutics, Inc.
Peer
|
+306.1% | +356.6% | +129.0% | +36.8% | +9.2% | +7.2% |
|
GRFS
Grifols, S.A.
Peer
|
-51.1% | +11.6% | +28.0% | -11.9% | +2.2% | -0.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GKOS
Glaukos Corporation
|
NEUTRAL | $7.14B | - | -26.4% | -37.0% | $122.07 | |
|
KYMR
Kymera Therapeutics, Inc.
|
NEUTRAL | $6.94B | - | -25.8% | -% | $85.05 | Compare |
|
IBRX
ImmunityBio, Inc.
|
NEUTRAL | $7.52B | - | -% | -% | $7.28 | Compare |
|
PTGX
Protagonist Therapeutics, Inc.
|
NEUTRAL | $6.76B | - | -20.2% | -282.8% | $105.98 | Compare |
|
GRFS
Grifols, S.A.
|
NEUTRAL | $6.74B | 12.83 | 6.2% | 5.3% | $8.21 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-10 | NAVRATIL TOMAS | Officer | Sale | 2,093 | $246,175 |
| 2026-04-01 | BURNS THOMAS WILLIAM | Chief Executive Officer | Gift | 180,308 | - |
| 2026-03-25 | GILLIAM JOSEPH E. | President | Stock Award | 23,621 | - |
| 2026-03-25 | THURMAN ALEX R. | Chief Financial Officer | Stock Award | 3,303 | - |
| 2026-03-25 | THURMAN ALEX R. | Chief Financial Officer | Sale | 2,511 | $267,321 |
| 2026-03-25 | NAVRATIL TOMAS | Officer | Stock Award | 32,781 | - |
| 2026-03-25 | BURNS THOMAS WILLIAM | Chief Executive Officer | Stock Award | 23,564 | - |
| 2026-03-24 | THURMAN ALEX R. | Chief Financial Officer | Sale | 1,521 | $160,070 |
| 2026-03-17 | THURMAN ALEX R. | Chief Financial Officer | Sale | 625 | $61,969 |
| 2026-03-16 | NAVRATIL TOMAS | Officer | Sale | 1,031 | $101,078 |
| 2026-02-19 | WEISNER AIMEE S | Director | Gift | 980 | - |
| 2026-02-19 | WEISNER AIMEE S | Director | Sale | 15,000 | $1,760,761 |
| 2026-02-19 | WEISNER AIMEE S | Director | Option Exercise | 15,000 | $370,350 |
| 2026-02-09 | BURNS THOMAS WILLIAM | Chief Executive Officer | Option Exercise | 166,000 | $5,132,720 |
| 2026-02-06 | BURNS THOMAS WILLIAM | Chief Executive Officer | Gift | 67,353 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
GKOS generates revenue from the commercialization of ophthalmology therapies, including iDose TR, iStent, and Photrexa, primarily through a direct sales organization in the U.S. and a mix of subsidiaries and distributors internationally. The company operates as a single reportable segment focused on selling these products to surgery centers, hospitals, and private practices. Specific financial metrics and detailed risk factors were not provided in the excerpt.
GKOS generates revenue through the commercialization of ophthalmology therapies, including the iStent family and iDose TR, sold via direct sales and independent distributors to surgery centers, hospitals, and private practices. Financial performance is subject to revenue recognition estimates for commercial and governmental rebates. While specific risk factors were referenced in the filing, detailed descriptions were not provided in the excerpt.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning GKOS from our newsroom.